Pharmafile Logo

News and Press Releases

Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease

19 September 2024 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: September 19, 2024

Tiziana Life Sciences
info@tizianalifesciences.com
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom

AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease

Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD FDA Fast Track...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 17, 2024

AC Immune
info@acimmune.com
EPFL Innovation Park-Building B 1015 Lausanne / Switzerland

Eisai Named on TIME100 Most Influential Companies 2024 List

3 June 2024 -- Tokyo, Japan -- Eisai Co announced today that TIME has selected Eisai as one of the TIME100 Most Influential Companies of 2024. TIME reveals the TIME100...

Category: Biotechnology, Other
Posted: June 3, 2024

Eisai
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Safety of ALX-001 reinforced by new data presented at AD/PD 2024 Conference in Lisbon, Portugal Two oral doses selected for further study in Alzheimer’s and Parkinson’s disease patients. 11 March 2024...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 11, 2024

Allyx Therapeutics
info@allyxthera.com
555 Long Wharf Drive Floor 11 New Haven, CT 06511, US

New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood

Blood-based diagnostic effectively discriminated between patients who were positive versus negative for amyloid beta on PET scans Data will be shared in a poster presentation at AD/PD 2024 on 8-9...

Category: Biotechnology
Posted: March 5, 2024

Sunbird Bio
35 Cambridgepark Drive Suite 100 Cambridge, MA 02140

PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Diseases

New collaboration will enhance ability to identify those more at risk of developing brain diseases to enable earlier interventions 29 February 2024 -- Manchester, UK -- PharmaKure, a clinical stage...

Category: Other
Posted: February 29, 2024

PharmaKure
info@pharmakure.com
Alderley Park Congleton Road Nether Alderley Open Access Lab 19S6 Macclesfield SK10 4TG

Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer’s disease transgenic model to be presented at AD/PD 2024 Conference

Galimedix’s novel, orally administered small molecule offers the hope of changing the course of disease by targeting amyloid beta oligomers and protofibrils 28 February 2024 -- Maryland, US -- Galimedix...

Category: Biotechnology
Posted: February 28, 2024

Galimedix Therapeutics
info@galimedix.com
3704 Calvend Lane Kensington, MD 20895 USA

PharmaKure announces study success for novel blood test to identify biomarkers in patients with Alzheimer’s Disease

Study confirms ALZmetrix whole blood test can detect people at high risk of developing full Alzheimer’s Disease 17 October 2023 -- Manchester, UK -- PharmaKure, a pharmaceutical company spun out...

Category: Clinical Trials, Drug Discovery
Posted: October 17, 2023

PharmaKure
info@pharmakure.com
Alderley Park Congleton Road Nether Alderley Open Access Lab 19S6 Macclesfield SK10 4TG